TME Pharma N.V.

ENXTPA:ALTME Stock Report

Market Cap: €6.6m

TME Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Aram Mangasarian

Chief executive officer

€673.3k

Total compensation

CEO salary percentage37.1%
CEO tenure9.5yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure3.9yrs

Recent management updates

Recent updates

Will NOXXON Pharma (EPA:ALNOX) Spend Its Cash Wisely?

Dec 20
Will NOXXON Pharma (EPA:ALNOX) Spend Its Cash Wisely?

We're Keeping An Eye On NOXXON Pharma's (EPA:ALNOX) Cash Burn Rate

Sep 06
We're Keeping An Eye On NOXXON Pharma's (EPA:ALNOX) Cash Burn Rate

Is NOXXON Pharma (EPA:ALNOX) In A Good Position To Invest In Growth?

May 19
Is NOXXON Pharma (EPA:ALNOX) In A Good Position To Invest In Growth?

NOXXON Pharma (EPA:ALNOX) Is In A Good Position To Deliver On Growth Plans

Feb 01
NOXXON Pharma (EPA:ALNOX) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Aram Mangasarian's remuneration changed compared to TME Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€6m

Mar 31 2024n/an/a

-€7m

Dec 31 2023€673k€250k

-€7m

Sep 30 2023n/an/a

-€8m

Jun 30 2023n/an/a

-€8m

Mar 31 2023n/an/a

-€12m

Dec 31 2022€690k€250k

-€15m

Sep 30 2022n/an/a

-€17m

Jun 30 2022n/an/a

-€18m

Mar 31 2022n/an/a

-€16m

Dec 31 2021€710k€250k

-€14m

Sep 30 2021n/an/a

-€13m

Jun 30 2021n/an/a

-€11m

Mar 31 2021n/an/a

-€11m

Dec 31 2020€539k€250k

-€10m

Sep 30 2020n/an/a

-€8m

Jun 30 2020n/an/a

-€5m

Mar 31 2020n/an/a

-€3m

Dec 31 2019€383k€250k

-€861k

Sep 30 2019n/an/a

-€5m

Jun 30 2019n/an/a

-€9m

Mar 31 2019n/an/a

-€10m

Dec 31 2018€561k€250k

-€11m

Compensation vs Market: Aram's total compensation ($USD692.43K) is above average for companies of similar size in the French market ($USD306.97K).

Compensation vs Earnings: Aram's compensation has been consistent with company performance over the past year.

CEO

Aram Mangasarian (54 yo)

9.5yrs

Tenure

€673,251

Compensation

Dr. Aram Mangasarian, M.B.A., Ph D., has been the Chief Executive Officer and Member of Executive Board at TME Pharma N.V. (formerly known as NOXXON Pharma N.V.) (formerly known as NOXXON Pharma AG) since...

Board Members

NamePositionTenureCompensationOwnership
Maurizio PetitBon
Independent Chairman of the Supervisory Board9yrsno datano data
Daniel Von Hoff
Member of Scientific Advisory Board3.9yrsno datano data
Lee Schalop
Member of the Supervisory Boardless than a yearno datano data
Alexandra Glucksmann
Member of Supervisory Boardless than a yearno datano data
Cornelis Izeboud
Independent Member of Supervisory Board4.6yrs€43.70kno data
Susan Coles
Independent Deputy Chair of Supervisory Board3.6yrs€43.60kno data
Jose Saro
Chairman of Scientific Advisory Board3.9yrsno datano data
Gabriela Chiorean
Member of Scientific Advisory Board3.9yrsno datano data
Eileen O'Reilly
Member of Scientific Advisory Board3.9yrsno datano data
Thomas T. Seufferlein
Member of Scientific Advisory Board3.9yrsno datano data
Michael Lim
Member of Scientific Advisory Board2.7yrsno datano data
Monika Hegi
Member of Scientific Advisory Board2.7yrsno datano data

3.9yrs

Average Tenure

65yo

Average Age

Experienced Board: ALTME's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 00:23
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TME Pharma N.V. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jean-Pierre LozaIn Extenso Financement & Marché
Benjamin IsaacsonScotiabank Global Banking and Market